Novamigra Therapeutics is a biotechnology research organisation engaged in advancing a novel approach to migraine prophylaxis.
Novamigra Therapeutics has raised $3.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.
Novamigra Therapeutics's investors include SZTA, PMK Ventures, The Vascular Group.
Novamigra Therapeutics is headquartered in Budapest, Hungary.
Novamigra Therapeutics is a biotechnology research organisation engaged in advancing a novel approach to migraine prophylaxis.
Novamigra Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Novamigra Therapeutics — Funding & Investors." VCBacked, January 9, 2026, https://www.vcbacked.co/company/novamigra-therapeutics. Accessed August 15, 2026.
VCBacked. (2026). Novamigra Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/novamigra-therapeutics
{{cite web |title=Novamigra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/novamigra-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated